Last Updated : May 1, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Sensipar | Cinacalcet hydrochloride | Secondary hyper-parathyroidism in chronic kidney disease | Do not list | Complete | ||
| Relpax | Eletriptan hydrobromide | Migraine | Do not list | Complete | ||
| Amevive | Alefacept | Psoriasis, moderate to severe chronic plaque | Do not list | Complete | ||
| Ebixa | Memantine hydrochloride | Dementia (Alzheimer type), moderate to severe | Do not list | Complete | ||
| Norprolac | Quinagolide hydrochloride | Hyperprolactinemia | Do not list | Complete | ||
| Fabrazyme | Agalsidase beta | Fabry Disease | Do not list | Complete | ||
| Strattera | Atomoxetine hydrochloride | Attention deficit hyperactivity disorder | Do not list | Complete | ||
| Aldurazyme | Laronidase | Mucopolysarccharidosis 1 (MPS 1), Hurler, Hurler-Scheie, Scheie | Do not list | Complete | ||
| Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | Do not list | Complete | ||
| Lyrica | Pregabalin | Pain, Neuropathic | Do not list | Complete |
Last Updated : May 1, 2024